INTRODUCTION
The importance of cardiovascular risk factors (CRF) in the development of coronary heart disease (CHD) is well established, and it is widely recognized that they must be controlled in order to halt the progression of the disorder. [1] However, some patients with CHD do not present classical CRFs. Although these patients are managed similarly to patients that have CRFs, they sometimes show differences as compared to those with CRFs. In spite of this, less attention has been paid to this subgroup.
In recent years there has been growing interest in the role of prognostic biomarkers in atherothrombosis. It has been shown that increased levels of high-sensitivity C reactive protein (hs-CRP), monocyte chemoattractant protein-1 (MCP-1), galectin-3, and N-terminal probrain natriuretic peptide (NT-proBNP) are related to an adverse prognosis. [2] [3] [4] [5] [6] [7] [8] More recently, plasma levels of the components of mineral metabolism, such as vitamin D, fibroblast growth factor-23 (FGF-23), parathormone, and phosphate have also been related to cardiovascular disorders. [9] [10] [11] [12] We have investigated whether CHD patients who do not have CRFs present a more favorable profile of prognostic biomarkers related to atherothrombosis. We divided a population of 704 patients with CHD into those with and without CRFs. These patients were examined according to a panel of biomarkers related to inflammation, thrombosis, renal damage, and heart failure: hs-CRP, MCP-1, galectin-3, and NT-pro-BNP. [2] [3] [4] [5] [6] [7] [8] In addition, we determined the levels of the components of mineral metabolism in the patients' plasma: calcidiol (a metabolite of vitamin D), FGF-23, parathormone, and phosphate.
METHODS

Patients
The research protocol was approved by the ethics committees of the participating hospitals and all patients signed informed consent documents. The BACS & BAMI (Biomarkers in Acute Coronary Syndrome & Biomarkers in Acute Myocardial Infarction) studies included patients admitted to four hospitals in Madrid who had either non-ST elevation acute coronary 4 syndrome or ST-elevation acute myocardial infarction, as described previously. [5] Exclusion criteria were: age over 85 years, coexistence of other significant cardiac disorders except left ventricular hypertrophy secondary to hypertension, coexistence of any illness or toxic habits that could limit patient survival, impossibility to perform revascularization when indicated, and subjects in whom follow-up was not possible. In order to limit the variability of the findings due to an excessive heterogeneity in the intervals between the acute event and blood extraction, the investigators agreed to exclude patients who were not clinically stable at day six of the index event.
In addition to plasma withdrawal at discharge, a second plasma sample was extracted on an outpatient basis between six and twelve months later, on an outpatient basis. This paper reports data from the clinical and analytic findings obtained during this second plasma extraction.
Between July 2006 and April 2010, 1,898 patients who had experienced an acute coronary event were discharged from the participating hospitals. Of these, 838 were included in the study. The remaining patients were not included due one of the following reasons: age over 85 years (17.3%), disorders or toxic habits limiting survival (29.0%), impossibility to perform cardiac revascularization (14.5%), coexistence of other significant cardiopathy (6.8%), impossibility to perform follow-up (12.0%), clinical instability beyond the sixth day at the index event (9.1%), refusal to participate in the study (2.0%), and impossibility of the investigators to include them (9.3%). Of the patients included, 7 died before the second plasma extraction and 709 had available and adequate plasma samples at the time. This visit took place between January 2007 and February 2011. The patients were included in a follow-up study, with the last visits taking place in May 2012. Five patients were lost to follow-up, leaving a total of 704 patients for analysis.
Study Design
The cross-sectional sudy was carried out during the visit performed six to twelve months after the acute coronary event. Blood was withdrawn from the patients for plasma storage and a complete set of clinical variables was recorded. Twelve-hour fasting venous blood samples were collected in ethylenediaminetetraacetate tube (EDTA). Patients were considered to present hypertension if they had a history of systolic and/or diastolic pressure equal to or higher than 140 and 90 mm Hg, respectively [13] or if they were taking blood-pressurelowering drugs for this disorder. Patients with current or past tobacco use were considered smokers. Patients receiving lipid-lowering therapy for this diagnosis and those with fasting lipid levels (LDL cholesterol>160 mg/dl and/or triglyceride levels>200 mg/dl) were considered to be diagnosed with dyslipidemia. [14] Patients were considered to present a family history of atherosclerosis when a first-degree relative younger than 60 years had history of CHD, peripheral vascular disease or cerebrovascular diease. [15] Finally, patients were considered to be diabetics if they were receiving therapy for the disease or if they had fasting glucose levels > 126 mg/dl. [16] A prospective observational study was also initiated during this visit. Under the study, patients were seen every year at their hospital. At the end of follow-up (maximum 4.6 years), the patients' medical records were reviewed and patient status was confirmed by telephone contact made by a cardiologist. The outcome variable was the combination of acute thrombotic events (any acute coronary syndrome, stroke, and transient ischemic attack) plus all-cause mortality and heart failure, defined as described previously. [5] Biomarker and analytical studies Venous blood samples were centrifuged at 2,500 g for 10 minutes. Plasma was stored at Diagnostics, Mannheim, Germany). Plasma concentrations of MCP-1 and galectin-3 were determined in duplicate using commercially available enzyme-linked immunosorbent assay kits (BMS279/2 Bender MedSystems, and DCP00, R&D Systems, respectively) following the manufacters' instructions. Intra-and inter-assay coefficients of variation were 4.6% and 5.9%
for MCP-1 and 6.2% and 8.3% for galectin-3, respectively. Hs-CRP was assessed by latexenhanced immunoturbidimetry (ADVIA 2400 Chemistry System, Siemens, Germany), and NTpro-BNP was analyzed by immunoassay (VITROS, Orthoclinical Diagnostics, U.S.A.). Lipids, glucose, and creatinine determinations were performed by standard methods (ADVIA 2400
Chemistry System, Siemens, Germany).
Statistical analysis
Quantitative data that followed a normal distribution are presented as mean±standard deviation and compared using the Student "t" test. When normal distribution could not be assumed, median (interquartile range) and Mann-Whitney test were used. Qualitative variables are displayed as percentages and were compared by X 2 or Fisher exact test where appropriate.
Log-rank test were used to compare time to outcome in patients without CRFs against those who had CRFs. Cox regression analysis was performed with forward, stepwise selection, to assess the predictive value of the biomarkers studied for the development of the outcome, controlling for all the variables shown in Table 1 . Analyses were performed with SPSS 19.0 (SPSS Inc., New York) and R 3.0.1. (http://www.r.project.org/).
RESULTS
Of the 704 patients included, only 20 (2.8%) did not present any classical CRFs. Forty percent of these patients were women (Table 1) . Age was similar in the non-CRF and the CRF groups, and there were no significant differences in the clinical variables between both groups, with the exception of the intake of antidiabetic drugs, which was more frequent in the CRF transitory ischemic attacks, 16 hospital admissions due to heart failure and 22 deaths. Twelve patients developed two events and 5 patients experienced three events. There were no significant differences between the two groups (P=0.816, log-rank test).
All variables shown in Table 1 were entered into a multivariate Cox model to investigate the predictive value of the biomarkers studied in the whole population. In this analysis, low calcidiol and high FGF-23 and MCP-1 plasma levels were independent predictors of outcome, along with age, insulin, and angiotensin converting enzyme inhibitors or angiotensin receptor blockers treatment (Table 2) .
DISCUSSION
Most patients with established CHD have some classical CRF. Nonetheless, a small proportion of them are free of CRFs. However, little attention has been paid to these patients.
Only 20 out of the 704 patients (2.8%) included in our study had no CRFs. This value is lower than those reported previously. (17) The published data vary depending on the population analyzed, cutoff values used in the definition of CRFs, and age. Age is considered an independent CRF, [1] and the proportion of patients without classical CRFs increases with age
[17] as we observed in our study. Male gender is also correlated with higher cardiovascular risk, [18] and in our population there was a higher proportion of men than women. However, we did not find significant differences in gender distribution between patients with and without CRFs, although this could be due to the small number of patients without CRFs.
Both groups showed a similar distribution of clinical variables; the only exception to this was that the CRF group contained more patients under oral antidiabetic therapy. This difference is logical as, by definition, diabetic patients could only belong to the CRF group.
Although similar data could be expected to be present with regard to the use of lipid and blood pressure lowering drugs, this was not the case. The percentage of patients receiving treatment with statins was similar in both groups, because aggressive lipid lowering is indicated in all patients after an acute coronary event. [19] With regard to antihypertensive patients, modulators of the renin-angiotensin system are indicated in subjects with clinically evident atherosclerosis, and even more when left ventricular dysfunction is present. [19] Similarly, beta-blockers are beneficial in patients with a history of myocardial infarction. [19] Other blood pressure lowering drugs such as diuretics may be adviced in more patients in addition to those with hypertension, such as patients who have experienced heart failure. Finally, patients without CRFs had lower glycemia, higher HDL-cholesterol, and lower triglyceride plasma levels than those with CRFs, according to the criteria used to allocate them into one of the two groups.
Inflammation is an important process both in atherogenesis and plaque complication. [20] In this regard, hs-CRP plasma levels have been associated with an increased incidence of cardiovascular events. [2, 3] In our study, patients without CRFs had lower hs-CRP levels than those with classical CRFs. Accordingly, MCP-1 plasma levels were also lower in patients without CRFs. MCP-1 is the most important chemokine involved in the atherothrombotic process, and it is vital to the recruitment of macrophages into the vessel wall. [21] It is expressed more strongly in atherosclerotic lesions than in the healthy vessel. [22] Drugs with antiatherosclerotic effects, such as statins, decrease MCP-1 expression in the vascular wall. [23] Furthermore, MCP-1 also has procoagulant properties. [24] According to this evidence, increased MCP-1 plasma levels have been found to predict the development of adverse cardiovascular events in patients with acute coronary syndromes and stable CHD. [4, 5] Although traditionally related to renal disease, abnormalities in mineral metabolism [11, [26] [27] [28] [29] In our population, subjects without
CRFs not only exhibited lower FGF-23 plasma levels, but also revealed increased calcidiol levels. This is especially important, since the combination of vitamin D deficit along with increased FGF-23 plasma levels seems to confer a higher cardiovascular risk. [30] The diminution in hs-CRP, MCP-1, and FGF-23 plasma levels, along with the increase in calcidiol levels seems to correlate with a more favorable prognosis in patients without CRFs.
Although this improved prognosis was not confirmed in our population, this could be due to the low number of patients that had no CRFs. Given the very low percentage of CHD patients without CRFs, confirmation of a better prognosis would require a very large sample size.
However, we show than in our whole population low calcidiol and high MCP-1 and FGF-23 plasma levels were independent predictors of the outcome, suggesting that the biomarker profile on non-CRF patients may be related with a more favorable prognosis.
This work has some limitations. Excluding patients with clinical instability in the first days after the index event could have introduced a certain bias, because these patients would probably have had a worse prognosis, and could have also a different distribution of CRFs. The low number of patients without CRF in our population could have limited the statistical power in the prognosis assessment. This suggests that very large sample sizes of patients with CHD must be examined in order to reach more sound conclusions with regard to potential differences in the prognosis of both groups. Finally, it must be emphasized that we have published previously Cox regression analyses in this population to explore separately the predictive power of MCP-1 [5] and that of calcidiol and FGF-23 plasma levels [30] . In the present paper, we have
